Eligen® Technology Publications

Eligen® Technology Publications

GLP-1 and PYY

  • Pharmacokinetics and pharmacodynamic effects of oral GLP‐1 and PYY3‐36: a proof‐of‐concept study in healthy subjects; Beglinger, C., et. al. Clin Pharm Therapeutics, 2008, 84, 468-474. DOI: 10.1038/clpt.2008.35

Clinical Abstract

  • Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects; Steinert, R. E., et. al. Am J Clin Nutr, 2010, 92, 810

Clinical Abstract

S-Calcitonin

  • Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials; Karsdal, M. A., et. al. J Clin Pharm, 2011, 51, 460-471. DOI: 10.1177/0091270010372625.

Clinical Abstract

  • Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamics efficacy; Karsdal, M. A., et. al. Eur J Clin Pharm, 2010, 66, 29-471.  DOI: 10.1007/s00228-009-0735-3.

Clinical Abstract

Gallium

  • Initial phase I clinical and pharmacokinetic assessment of G4544, an oral gallium containing compound; Novick, S. C., et. al. J Clin Oncology, 2008, 26 (No. 15S), 8592.

Clinical Abstract

Heparin & Low Molecular Weight Heparin (LMWH)

  • Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty; Berkowitz, S. D., et. al. J Thromb Haemostasis, 2003, 1, 1914-1919.

Clinical Abstract

  • Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects; Mousa, S. A., et. al. J Clin Pharm, 2007, 47, 1508-1520.

Clinical Abstract

Parathyroide hormone (PTH)

  • The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women; Hammerle, S. P., et. al. Bone, 2012, 50, 965-973.

Clinical Abstract

Ibandronate

  • Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC); Bittner, B., et. al. Pharmazie, 2011, 67, 233-241.

Clinical Abstract

  • Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women; McIntyre, C., et. al. J Drug Deliv Sci Tech, 2011, 21, 521-525.

Clinical Abstract

  • Drug-drug interaction study between a novel oral ibandronate formulation and metformin; Bittner, B., et. al. Arzneimittelforschung 2011, 61, 707-713. doi:10.1055/s-0031-1300591

Clinical Abstract